Your browser is no longer supported. Please, upgrade your browser.
Settings
EYEG [NASD]
EyeGate Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-1.68 Insider Own1.00% Shs Outstand7.06M Perf Week1.11%
Market Cap21.84M Forward P/E- EPS next Y-0.88 Insider Trans-96.60% Shs Float- Perf Month19.74%
Income-9.50M PEG- EPS next Q-0.31 Inst Own31.60% Short Float- Perf Quarter-60.61%
Sales0.01M P/S1811.10 EPS this Y20.70% Inst Trans0.74% Short Ratio0.04 Perf Half Y-66.73%
Book/sh1.48 P/B1.23 EPS next Y35.10% ROA-60.00% Target Price- Perf Year-50.54%
Cash/sh0.31 P/C5.90 EPS next 5Y- ROE-105.00% 52W Range1.44 - 8.18 Perf YTD-63.08%
Dividend- P/FCF- EPS past 5Y46.50% ROI- 52W High-77.50% Beta1.07
Dividend %- Quick Ratio3.10 Sales past 5Y- Gross Margin- 52W Low27.78% ATR0.17
Employees14 Current Ratio3.10 Sales Q/Q- Oper. Margin- RSI (14)47.49 Volatility11.55% 9.11%
OptionableNo Debt/Eq0.00 EPS Q/Q7.60% Profit Margin- Rel Volume0.78 Prev Close1.82
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume2.14M Price1.84
Recom2.00 SMA204.97% SMA50-17.76% SMA200-57.29% Volume247,357 Change1.10%
Dec-22-20Reiterated H.C. Wainwright Buy $10 → $14
Nov-12-20Reiterated H.C. Wainwright Buy $12 → $10
Feb-06-18Reiterated H.C. Wainwright Buy $5 → $3
Apr-07-16Initiated Noble Financial Buy $10
Feb-01-16Initiated Rodman & Renshaw Buy $10
Dec-23-15Initiated Chardan Capital Markets Buy $6
Nov-12-15Initiated Maxim Group Buy $11
Sep-14-21 12:04PM  
07:13AM  
Sep-09-21 04:15PM  
Sep-08-21 06:55AM  
Aug-12-21 04:15PM  
Aug-11-21 04:15PM  
Aug-10-21 06:55AM  
Jul-27-21 08:26AM  
05:56AM  
Jul-26-21 04:15PM  
Jun-30-21 09:56AM  
Jun-14-21 06:55AM  
May-18-21 05:46AM  
May-12-21 04:15PM  
Apr-01-21 06:55AM  
Mar-25-21 04:15PM  
Feb-01-21 06:55AM  
Jan-06-21 06:55AM  
Dec-30-20 08:00AM  
Dec-21-20 10:10AM  
08:12AM  
06:55AM  
Nov-30-20 04:38AM  
Nov-09-20 04:15PM  
Sep-28-20 11:05AM  
Sep-25-20 10:48AM  
Sep-08-20 06:55AM  
Aug-12-20 06:55AM  
Aug-06-20 04:15PM  
Jul-14-20 06:55AM  
Jun-11-20 06:55AM  
Jun-01-20 06:55AM  
May-19-20 09:11AM  
May-06-20 04:15PM  
09:10AM  
Apr-01-20 09:04AM  
Mar-31-20 06:55AM  
Mar-04-20 04:15PM  
Jan-06-20 06:55AM  
Jan-03-20 10:25AM  
Dec-31-19 09:25AM  
Dec-17-19 06:55AM  
Dec-02-19 06:55AM  
Nov-22-19 09:02AM  
08:37AM  
06:55AM  
Nov-14-19 10:15AM  
Nov-07-19 06:55AM  
Oct-09-19 06:55AM  
06:55AM  
Sep-30-19 06:55AM  
Sep-23-19 06:55AM  
Sep-16-19 06:55AM  
Sep-03-19 06:55AM  
Aug-29-19 12:45PM  
Aug-26-19 06:55AM  
Aug-08-19 06:55AM  
Aug-05-19 12:21PM  
09:00AM  
06:55AM  
Jul-31-19 06:55AM  
Jul-09-19 06:55AM  
Jun-26-19 06:55AM  
Jun-05-19 10:00AM  
Jun-03-19 06:55AM  
May-14-19 06:55AM  
May-08-19 04:15PM  
May-02-19 02:00PM  
06:55AM  
Mar-28-19 10:00AM  
Mar-26-19 06:55AM  
Mar-01-19 04:05PM  
Jan-29-19 06:55AM  
Jan-16-19 06:55AM  
Nov-30-18 12:30PM  
Nov-21-18 08:45AM  
Nov-14-18 11:20AM  
06:50AM  
Nov-13-18 04:05PM  
09:50AM  
06:55AM  
06:55AM  
Oct-02-18 06:55AM  
Sep-28-18 11:45AM  
Sep-25-18 06:55AM  
Sep-24-18 06:55AM  
Sep-04-18 08:31AM  
08:30AM  
Aug-29-18 08:30AM  
Aug-20-18 08:30AM  
Aug-07-18 08:30AM  
Aug-03-18 08:30AM  
Jul-26-18 09:30AM  
09:20AM  
Jul-24-18 08:30AM  
Jul-10-18 07:45AM  
Jun-22-18 08:30AM  
Jun-11-18 07:00AM  
May-30-18 08:30AM  
May-29-18 10:35AM  
EyeGate Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on developing and commercializing products for treating inflammatory and immune diseases with a focus on the eye and nervous system in the United States. It develops PP-001, a clinical stage dihydroorotate dehydrogenase inhibitor that has been developed in two clinical-stage ophthalmic formulations, consisting of PaniJect that is in Phase Ia/IIb clinical trial for multiple diseases that affect the posterior region of the eye, including non-infectious posterior uveitis and diabetic macular edema; and PaniDrop, which is in Phase I safety study for multiple diseases that affect the ocular surface and anterior region of the eye, comprising of allergic conjunctivitis, viral conjunctivitis, and dry eye disease. The company also develops ocular bandage gel, a modified form of the natural polymer hyaluronic acid for corneal wound repair, and punctate epitheliopathies with a focus on dry eye. The company has license agreements with BioTime, Inc. Eyegate Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Waltham, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
ARMISTICE CAPITAL, LLC10% OwnerAug 02Sale2.40192,775463,046785,000Aug 03 05:09 PM
ARMISTICE CAPITAL, LLC10% OwnerJul 30Sale2.6968,188183,562977,775Aug 03 05:09 PM
ARMISTICE CAPITAL, LLCDirectorJul 29Sale3.00400,0001,200,0001,045,963Jul 29 07:59 PM
ARMISTICE CAPITAL, LLCDirectorJul 28Sale3.28375,4431,232,6171,445,963Jul 29 07:59 PM
ARMISTICE CAPITAL, LLCDirectorJul 27Sale5.092,377,69512,113,6471,821,406Jul 29 07:59 PM
ARMISTICE CAPITAL, LLCDirectorJan 06Buy5.221,531,1018,000,0033,346,601Jan 08 08:31 PM